Transport of drugs across the blood-brain barrier in Alzheimer's disease

Therapeutic Delivery

Volumn 1, Issue 4, 2010, Pages 595-611

  Nicolazzo, Joseph A ^a   Mehta, Dharmini C ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ALBUMIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; ANG 1005; ANG 1007; BREAST CANCER RESISTANCE PROTEIN; CLIOQUINOL; DIAZEPAM; DOXORUBICIN; ETOPOSIDE; FLUORESCEIN SODIUM; GLYCOPROTEIN P; IMMUNOGLOBULIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; BRAIN BLOOD FLOW; CAPILLARY WALL; CAUSAL ATTRIBUTION; CLINICAL FEATURE; DRUG DELIVERY SYSTEM; DRUG TRANSPORT; HUMAN; MEMBRANE PERMEABILITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW;

EID: 79954483841     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.10.41     Document Type: Review

References (169)

1. Abbott NJ. Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology. Neurochem. Int. 45(4), 545-552 (2004). (Pubitemid 38739482)
2. Pardridge WM. Brain Drug Targeting: The Future of Brain Drug Development. Cambridge University Press, Cambridge, UK (2001).
3. Schlageter KE, Molnar P, Lapin GD, Groothuis DR. Microvessel organization and structure in experimental brain tumors: microvessel populations with distinctive structural and functional properties. Microvasc. Res. 58(3), 312-328 (1999). (Pubitemid 29531878)
4. Pardridge WM. William Pardridge discusses the lack of BBB research. Interview by Rebecca N Lawrence. Drug Discov. Today 7(4), 223-226 (2002).
5. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2(1), 3-14 (2005). (Pubitemid 40128022)
6. Reese TS, Karnovsky MJ. Fine structural localization of a blood-brain barrier to exogenous peroxidase. J. Cell Biol. 34(1), 207-217 (1967).
7. Brightman MW, Reese TS. Junctions between intimately apposed cell membranes in the vertebrate brain. J. Cell Biol. 40(3), 648-677 (1969).
8. Abbott NJ. Astrocyte-endothelial interactions and blood-brain barrier permeability. J. Anat. 200(6), 629-638 (2002). (Pubitemid 34823054)
9. Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol. Rev. 57(2), 173-185 (2005). (Pubitemid 41043883)
10. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 57(2), 178-201 (2008).
11. Gumbiner B, Lowenkopf T, Apatira D. Identification of a 160-kDa polypeptide that binds to the tight junction protein ZO-1. Proc. Natl Acad. Sci. USA 88(8), 3460-3464 (1991). (Pubitemid 21916641)
12. Haskins J, Gu L, Wittchen ES, Hibbard J, Stevenson BR. ZO-3, a novel member of the MAGUK protein family found at the tight junction, interacts with ZO-1 and occludin. J. Cell Biol. 141(1), 199-208 (1998). (Pubitemid 28182652)
13. Jesaitis LA, Goodenough DA. Molecular characterization and tissue distribution of ZO-2, a tight junction protein homologous to ZO-1 and the Drosophila discs-large tumor suppressor protein. J. Cell Biol. 124(6), 949-961 (1994). (Pubitemid 24109397)
14. Dallas S, Miller DS, Bendayan R. Multidrug resistance-associated proteins: expression and function in the central nervous system. Pharmacol. Rev. 58(2), 140-161 (2006).
15. Nicolazzo JA, Katneni K. Drug transport across the blood-brain barrier and the impact of breast cancer resistance protein (ABCG2). Curr. Top. Med. Chem. 9(2), 130-147 (2009).
16. Schinkel AH. P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv. Drug. Deliv. Rev. 36(2-3), 179-194 (1999). (Pubitemid 29121971)
17. Cole SP, Bhardwaj G, Gerlach JH et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258(5088), 1650-1654 (1992). (Pubitemid 23012438)
18. Doyle LA, Yang W, Abruzzo LV et al. A multidrug-resistance transporter from human MCF-7 breast cancer cells. Proc. Natl Acad. Sci. USA 95(26), 15665-15670 (1998). (Pubitemid 29018757)
19. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 455(1), 152-162 (1976).
20. Tamai I, Tsuji A. Transporter-mediated permeation of drugs across the blood-brain barrier. J. Pharm. Sci. 89(11), 1371-1388 (2000).
21. Dehouck B, Cecchelli R, Dehouck M. A co-culture of brain capillary endothelial cells and astrocytes: an in vitro blood-brain barrier for studying drug transport to the brain. In:Drug Transport Across the Blood-Brain Barrier - In vitro and In vivo Techniques. de Boer AG, Sutanto W (Eds), Harwood Academic Publishers, Amsterdam, The Netherlands, 69-79 (1997).
22. Rubin LL, Hall DE, Porter S et al. A cell culture model of the blood-brain barrier. J. Cell Biol. 115(6), 1725-1735 (1991). (Pubitemid 21910012)
23. Fenart L, Buée-Scherrer V, Descamps L et al. Inhibition of P-glycoprotein: rapid assessment of its implication in blood-brain barrier integrity and drug transport to the brain by an in vitro model of the blood-brain barrier. Pharm. Res. 15(7), 993-1000 (1998). (Pubitemid 28356913)
24. Gaillard PJ, van der Sandt ICJ, Voorwinden LH et al. Astrocytes increase the functional expression of P-glycoprotein in an in vitro model of the blood-brain barrier. Pharm. Res. 17(10), 1198-1205 (2000).
25. Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions. Circ. Res. 97(6), 512-523 (2005). (Pubitemid 41361741)
26. Hartmann C, Zozulya A, Wegener H, Galla HJ. The impact of glia-derived extracellular matrices on the barrier function of cerebral endothelial cells: an in vitro study. Exp. Cell Res. 313(7), 1318-1325 (2007). (Pubitemid 46507445)
27. Nakagawa S, Deli MA, Nakao S et al. Pericytes from brain microvessels strengthen the barrier integrity in primary cultures of rat brain endothelial cells. Cell Mol. Neurobiol. 27(6), 687-694 (2007). (Pubitemid 47476613)
28. Farkas E, Luiten PG. Cerebral microvascular pathology in aging and Alzheimer's disease. Prog. Neurobiol. 64(6), 575-611 (2001). (Pubitemid 32304447)
29. Savettieri G, Di Liegro I, Catania C et al. Neurons and ECM regulate occludin localization in brain endothelial cells. Neuroreport. 11(5), 1081-1084 (2000). (Pubitemid 30235459)
30. Tilling T, Korte D, Hoheisel D, Galla HJ. Basement membrane proteins influence brain capillary endothelial barrier function in vitro. J. Neurochem. 71(3), 1151-1157 (1998). (Pubitemid 28390269)
31. Upton RN. Cerebral uptake of drugs in humans. Clin. Exp. Pharmacol. Physiol. 34(8), 695-701 (2007). (Pubitemid 47013496)
32. Upton RN, Ludbrook GL, Grant C, Doolette DJ. The effect of altered cerebral blood flow on the cerebral kinetics of thiopental and propofol in sheep. Anesthesiology 93(4), 1085-1094 (2000).
33. Zwolinski BJ, Eyring H, Reese CE. Diffusion and membrane permeability. J. Phys. Chem. 53(9), 1426-1453 (1949).
34. de Vries HE, Kuiper J, De Boer AG, Van Berkel TJC, Breimer DD. The blood- brain barrier in neuroinflammatory diseases. Pharmacol. Rev. 49(2), 143-155 (1997). (Pubitemid 27291032)
35. Stolp HB, Dziegielewska KM. Role of developmental inflammation and blood-brain barrier dysfunction in neurodevelopmental and neurodegenerative disorders. Neuropath. Appl. Neurobiol. 35(2), 132-146 (2009).
36. Alzheimer's Asociation. 2010 Alzheimer's disease facts and figures. Alzheimers Dement. 6(2), 158-194 (2010).
37. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81(2), 741-766 (2001).
38. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of Ab42(43) and Ab40 in senile plaques with end-specific Ab monoclonals: evidence that an initially deposited species is Ab42(43). Neuron 13(1), 45-53 (1994).
39. Snyder SW, Ladror US, Wade WS et al. Amyloid-b aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths. Biophys. J. 67(3), 1216-1228 (1994).
40. Greenberg SM, Gurol ME, Rosand J, Smith EE. Amyloid angiopathy-related vascular cognitive impairment. Stroke 35(11 Suppl 1), 2616-2619 (2004) (Pubitemid 39458351)
41. Gravina SA, Ho L, Eckman CB et al. Amyloid b protein (Ab) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at Ab40 or Ab42(43). J. Biol. Chem. 270(13), 7013-7016 (1995).
42. McGowan E, Pickford F, Kim J et al. Ab42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 47(2), 191-199 (2005). (Pubitemid 41019251)
43. Roher AE, Lowenson JD, Clarke S et al. b-amyloid1-42 is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc. Natl Acad. Sci. USA 90(22), 10836-10840 (1993).
44. Bates KA, Verdile G, Li QX et al. Clearance mechanisms of Alzheimer's amyloid-b peptide: implications for therapeutic design and diagnostic tests. Mol. Psychiatry 14(5), 469-486 (2009).
45. Wang YJ, Zhou HD, Zhou XF. Clearance of amyloid-b in Alzheimer's disease: progress, problems and perspectives. Drug Discov. Today. 11(19-20), 931-938 (2006).
46. Bell RD, Zlokovic BV. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol. 118(1), 103-113 (2009).
47. Saido TC, Iwata N. Metabolism of amyloid b peptide and pathogenesis of Alzheimer's disease. Towards presymptomatic diagnosis, prevention and therapy. Neurosci. Res. 54(4), 235-253 (2006). (Pubitemid 43374441)
48. Preston SD, Steart PV, Wilkinson A, Nicoll JA, Weller RO. Capillary and arterial cerebral amyloid angiopathy in Alzheimer's disease: defining the perivascular route for the elimination of amyloid b from the human brain. Neuropath. Appl. Neurobiol. 29(2), 106-117 (2003). (Pubitemid 36408329)
49. Deane R, Zlokovic BV. Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease. Curr. Alzheimer Res. 4(2), 197-197 (2007).
50. Banks WA, Robinson SM, Verma S, Morley JE. Efflux of human and mouse amyloid b proteins 1-40 and 1-42 from brain: impairment in a mouse model of Alzheimer's disease. Neuroscience 12(2), 487-492 (2003). (Pubitemid 37176936)
51. Kandimalla KK, Curran GL, Holasek SS, Gilles EJ, Wengenack TM, Poduslo JF. Pharmacokinetic analysis of the blood-brain barrier transport of 125I-amyloid b protein 40 in wild-type and Alzheimer's disease transgenic mice (APP,PS1) and its implications for amyloid plaque formation. J. Pharmacol. Exp. Ther. 313(3), 1370-1380 (2005).
52. Zlokovic BV. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci. 28(4), 202-208 (2005).
53. de la Torre JC. Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma and dialectics. Lancet Neurol. 3(3), 184-190 (2004).
54. Kalaria RN. Cerebral vessels in aging and Alzheimer's disease. Pharmacol. Ther. 72(3), 193-214 (1996). (Pubitemid 26425810)
55. Kalaria RN. The blood-brain barrier and cerebrovascular pathology in Alzheimer's disease. Ann. N. Y. Acad. Sci. 893, 113-125 (1999). (Pubitemid 30038071)
56. Cutler MP, Deuel RM, Barlow CF. Albumin exchange between plasma and cerebrospinal fluid. Arch. Neurol. 17(3), 261-270 (1967).
57. Blennow K, Fredman P, Wallin A et al. Protein analysis in cerebrospinal fluid. II. Reference values derived from healthy individuals 18-88 years of age. Eur. Neurol. 33(2), 129-133 (1993). (Pubitemid 23100537)
58. Tibbling G, Link H, O'Hman S. Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand. J. Clin. Lab. Invest. 37(5), 385-390 (1977). (Pubitemid 8387871)
59. Eikelenboom P, Stam FC. Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study. Acta Neuropathol. 57(2-3), 239-242 (1982). (Pubitemid 12085182)
60. Ishii T, Haga S. Immuno-electron microscopic localization of immunoglobulins in amyloid fibrils of senile plaques. Acta Neuropathol. 36(3), 243-249 (1976).
61. Wisniewski HM, Kozlowski PB. Evidence for blood-brain barrier changes in senile dementia of the Alzheimer type (SDAT). Ann. N. Y. Acad. Sci. 396, 119-129 (1982). (Pubitemid 13073501)
62. Elovaara I, Palo J, Erkinjuntti T, Sulkava R. Serum and cerebrospinal fluid proteins and the blood-brain barrier in Alzheimer's disease and multi-infarct dementia. Eur. Neurol. 26(4), 229-234 (1987). (Pubitemid 17077709)
63. Skoog I, Wallin A, Fredman P et al. A population study on blood-brain barrier function in 85-year-olds. Neurology 50(4), 966-971 (1998).
64. Alafuzoff I, Adolfsson R, Bucht G, Winblad B. Albumin and immunoglobulin in plasma and cerebrospinal fluid, and blood-cerebrospinal fluid barrier function in patients with dementia of Alzheimer type and multi-infarct dementia. J. Neurol. Sci. 60(3), 465-472 (1983). (Pubitemid 13051197)
65. Blennow K, Wallin A, Fredman P, Karlsson I, Gottfries CG, Svennerholm L. Blood-brain barrier disturbance in patients with Alzheimer's disease is related to vascular factors. Acta. Neurol. Scand. 81(4), 323-326 (1990). (Pubitemid 20174132)
66. Hampel H, Muller-Spahn F, Berger C, Haberl A, Ackenheil M, Hock C. Evidence of blood-cerebrospinal fluid-barrier impairment in a subgroup of patients with dementia of the Alzheimer type and major depression: a possible indicator for immunoactivation. Dementia 6(6), 348-354 (1995).
67. Wada H. Blood-brain barrier permeability of the demented elderly as studied by cerebrospinal fluid-serum albumin ratio. Intern. Med. 37(6), 509-513 (1998). (Pubitemid 128520872)
68. Johanson CE, Duncan JA, Stopa EG, Baird A. Enhanced prospects for drug delivery and brain targeting by the choroid plexus-CSF route. Pharm. Res. 22(7), 1011-1037 (2005). (Pubitemid 41130789)
69. Algotsson A, Winblad B. The integrity of the blood-brain barrier in Alzheimer's disease. Acta. Neurol. Scand. 115(6), 403-408 (2007). (Pubitemid 46776325)
70. Bowman GL, Kaye JA, Moore M, Waichunas D, Carlson NE, Quinn JF. Blood-brain barrier impairment in Alzheimer disease: stability and functional significance. Neurology 68(1), 1809-1814 (2007). (Pubitemid 46791393)
71. Zipser BD, Johanson CE, Gonzales L et al. Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. Neurobiol. Aging 28(7), 977-986 (2007). (Pubitemid 46635913)
72. Alafuzoff I, Adolfsson R, Grundke-Iqbal I, Winblad B. Blood-brain barrier in Alzheimer dementia and in nondemented elderly. An immunocytochemical study. Acta Neuropathol. 73(2), 160-166 (1987). (Pubitemid 17060012)
73. Kay AD, May C, Papadopoulos NM et al. CSF and serum concentrations of albumin and IgG in Alzheimer's disease. Neurobiol. Aging 8(1), 21-25 (1987). (Pubitemid 17034561)
74. Mecocci P, Parnetti L, Reboldi GP et al. Blood-brain barrier in a geriatric population: barrier function in degenerative and vascular dementias. Acta Neurol. Scand. 84(3), 210-213 (1991).
75. Rozemuller JM, Eikelenboom P, Kamphorst W, Stam FC. Lack of evidence for dysfunction of the blood-brain barrier in Alzheimer's disease: an immunohistochemical study. Neurobiol. Aging 9(4), 383-391 (1988). (Pubitemid 19262071)
76. Frulich L, Kornhuber J, Ihl R, Fritze J, Maurer K, Riederer P. Integrity of the blood-CSF barrier in dementia of Alzheimer type: CSF/serum ratios of albumin and IgG. Eur. Arch. Psychiatry Clin. Neurosci. 240(6), 363-366 (1991).
77. Leonardi A, Gandolfo C, Caponnetto C, Arata L, Vecchia R. The integrity of the blood-brain barrier in Alzheimer's type and multi-infarct dementia evaluated by the study of albumin and IgG in serum and cerebrospinal fluid. J. Neurol. Sci. 67(2), 253-261 (1985). (Pubitemid 15130767)
78. Caserta MT, Caccioppo D, Lapin GD, Ragin A, Groothuis DR. Blood-brain barrier integrity in Alzheimer's disease patients and elderly control subjects. J. Neuropsychiatry Clin. Neurosci. 10(1), 78-84 (1998). (Pubitemid 28135127)
79. Friedland RP, Yano Y, Budinger TF et al. Quantitative evaluation of blood-brain barrier integrity in Alzheimer type dementia: positron emission tomographic studies with rubidium-82. Eur. Neurol. 22 (Suppl. 2), 15-20 (1983).
80. Schlageter NL, Carson RE, Rapoport SI. Examination of blood-brain barrier permeability in dementia of the Alzheimer type with [68Ga]EDTA and positron emission tomography. J. Cereb. Blood Flow Metab. 7(1), 1-8 (1987). (Pubitemid 17018308)
81. Starr JM, Farrall AJ, Armitage P, McGurn B, Wardlaw J. Blood-brain barrier permeability in Alzheimer's disease: a case-control MRI study. Psychiatry Res. 171(3), 232-241 (2009).
82. Farrall AJ, Wardlaw J. Blood-brain barrier: aging and microvascular disease - systematic review and meta-analysis. Neurobiol. Aging 30(3), 337-352 (2009).
83. Su GC, Arendash GW, Kalaria RN, Bjugstad KB, Mullan M. Intravascular infusions of soluble b-amyloid compromise the blood-brain barrier, activate CNS glial cells and induce peripheral hemorrhage. Brain Res. 818(1), 105-117 (1999). (Pubitemid 29227289)
84. Jancsó G, Domoki F, Suntha P et al. b-amyloid1-42 peptide impairs blood-brain barrier function after intracarotid infusion in rats. Neurosci. Lett. 253(2), 139-141 (1998). (Pubitemid 28430642)
85. Farkas IG, Czigner A, Farkas E et al. b-amyloid peptide-induced blood-brain barrier disruption facilitates T-cell entry into the rat brain. Acta Histochem. 105(2), 115-125 (2003). (Pubitemid 36734149)
86. Mehta PD, Pirttilu T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM. Plasma and cerebrospinal fluid levels of amyloid b proteins 1-40 and 1-42 in Alzheimer disease. Arch. Neurol. 57(1), 100-105 (2000). (Pubitemid 30027637)
87. Scheuner D, Eckman C, Jensen M et al. Secreted amyloid b-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2(8), 864-870 (1996). (Pubitemid 26296755)
88. Blanc EM, Toborek M, Mark RJ, Hennig B, Mattson MP. Amyloid b-peptide induces cell monolayer albumin permeability, impairs glucose transport, and induces apoptosis in vascular endothelial cells. J. Neurochem. 68(5), 1870-1881 (1997). (Pubitemid 27176122)
89. Strazielle N, Ghersi-Egea JF, Ghiso J et al. In vitro evidence that b-amyloid peptide 1-40 diffuses across the blood-brain barrier and affects its permeability. J. Neuropathol. Exp. Neurol. 59(1), 29-38 (2000). (Pubitemid 30069223)
90. Marco S, Skaper SD. Amyloid b-peptide1-42 alters tight junction protein distribution and expression in brain microvessel endothelial cells. Neurosci. Lett. 401(3), 219-224 (2006). (Pubitemid 44250979)
91. Gonzales-Velasques FJ, Kotarek JA, Moss MA. Soluble aggregates of the amyloid-b protein selectively stimulate permeability in human brain microvascular endothelial monolayers. J. Neurochem. 107(2), 466-477 (2008).
92. Weksler BB, Subileau EA, Perriure N et al. Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB 19(13), 1872-1874 (2005). (Pubitemid 41598779)
93. Tai LM, Holloway KA, Male DK, Loughlin AJ, Romero IA. Amyloid-b-induced occludin down-regulation and increased permeability in human brain endothelial cells is mediated by MAPK activation. J. Cell. Mol. Med. 14(5), 1101-12 (2010).
94. Ujiie M, Dickstein DL, Carlow DA, Jefferies WA. Blood-brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. Microcirculation 10(6), 463-470 (2003). (Pubitemid 39004272)
95. Oddo S, Caccamo A, Shepherd JD et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Ab and synaptic dysfunction. Neuron 39(3), 409-421 (2003). (Pubitemid 36937044)
96. Bourasset F, Mélissa O, Tremblay C et al. Reduction of the cerebrovascular volume in a transgenic mouse model of Alzheimer's disease. Neuropharmacology 56(4), 808-813 (2009).
97. Montaldi D, Brooks DN, McColl JH et al. Measurements of regional cerebral-blood flow and cognitive performance in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 53(1), 33-38 (1990). (Pubitemid 20034360)
98. O'Brien JT, Eagger S, Syed GM, Sahakian BJ, Levy R. A study of regional cerebral-blood flow and cognitive performance in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 55(12), 1182-1187 (1992). (Pubitemid 23010099)
99. Waldemar G, Bruhn P, Kristensen M, Johnsen A, Paulson OB, Lassen NA. Heterogeneity of neocortical cerebral blood flow deficits in dementia of the Alzheimer type: a [99mTc]-d,l-HMPAO SPECT study. J. Neurol. Neurosurg. Psychiatry 57(3), 285-295 (1994). (Pubitemid 24083411)
100. Mancardi GL, Perdelli F, Rivano C, Leonardi A, Bugiani O. Thickening of the basement membrane of cortical capillaries in Alzheimer's disease. Acta Neuropathol. 49(1), 79-83 (1980). (Pubitemid 10139968)
101. Vinters HV, Secor DL, Read SL et al. Microvasculature in brain biopsy specimens from patients with Alzheimer's disease: an immunohistochemical and ultrastructural study. Ultrastruct. Pathol. 18(3), 333-348 (1994). (Pubitemid 24184171)
102. Zarow C, Barron E, Chui HC, Perlmutter LS. Vascular basement membrane pathology and Alzheimer's disease. Ann. NY Acad. Sci. 826, 147-160 (1997). (Pubitemid 27478037)
103. Cheng Z, Zhang J, Liu H, Li Y, Zhao Y, Yang E. CNS penetration for small molecule therapeutics do not increase in multiple sclerosis (MS) and Alzheimer's disease (AD) related animal models despite reported blood-brain barrier disruption. Drug Metab. Dispos. 38(8), 1355-1361 (2010).
104. Kalaria RN, Pax AB. Increased collagen content of cerebral microvessels in Alzheimer's disease. Brain Res. 705(1-2), 349-352 (1995). (Pubitemid 26037378)
105. Tong XK, Nicolakakis N, Kocharyan A, Hamel E. Vascular remodeling versus amyloid b-induced oxidative stress in the cerebrovascular dysfunctions associated with Alzheimer's disease. J. Neurosci. 25(4), 11165-11174 (2005). (Pubitemid 43089561)
106. Du AT, Jahng GH, Hayasaka S et al. Hypoperfusion in frontotemporal dementia and Alzheimer disease by arterial spin labeling MRI. Neurology 67(7), 1215-1220 (2006). (Pubitemid 44563830)
107. Johnson NA, Jahng GH, Weiner MW et al. Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. Radiology 234(3), 851-859 (2005). (Pubitemid 40250829)
108. Beckmann N, Schuler A, Mueggler T et al. Age-dependent cerebrovascular abnormalities and blood flow disturbances in APP23 mice modeling Alzheimer's disease. J. Neurosci. 23(24), 8453-8459 (2003). (Pubitemid 37158744)
109. Niwa K, Kazama K, Younkin SG, Carlson GA, Iadecola C. Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein. Neurobiol. Dis. 9(1), 61-68 (2002). (Pubitemid 34174565)
110. Weidensteiner C, Metzger F, Bruns A, Bohrmann B, Kuennecke B, von Kienlin M. Cortical hypoperfusion in the B6.PS2APP mouse model for Alzheimer's disease: comprehensive phenotyping of vascular and tissular parameters by MRI. Magn. Reson. Med. 62(1), 35-45 (2009).
111. Dagenais C, Rousselle C, Pollack GM, Scherrmann JM. Development of an in situ mouse brain perfusion model and its application to MDR1A P-glycoprotein-deficient mice. J. Cereb. Blood Flow Metab. 20(2), 381-386 (2000). (Pubitemid 30108457)
112. Takasato Y, Rapoport SI, Smith QR. An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am. J. Physiol. 247(3 Pt 2), H484-H493 (1984). (Pubitemid 14047362)
113. Pardridge WM, Sakiyama R, Fierer G. Blood-brain barrier transport and brain sequestration of propranolol and lidocaine. Am. J. Physiol. 247, R582-R588 (1984). (Pubitemid 14003650)
114. Upton RN, Ludbrook GL, Martinez AM, Grant C, Milne RW. Cerebral and lung kinetics of morphine in conscious sheep after short intravenous infusions Br. J. Anaesth. 90(6), 750-758 (2003). (Pubitemid 36700779)
115. Herz J, Strickland DK. LRP: a multifunctional scavenger and signalling receptor. J. Clin. Invest. 108(6), 779-784 (2001). (Pubitemid 32880284)
116. Deane R, Wu Z, Sagare A et al. LRP/amyloid b-peptide interaction mediates differential brain efflux of Ab isoforms. Neuron. 43(3), 333-344 (2004). (Pubitemid 39061126)
117. Shibata M, Yamada S, Kumar SR et al. Clearance of Alzheimer's amyloid1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 106(12), 1489-1499 (2000). (Pubitemid 32038587)
118. Jaeger LB, Dohgu S, Hwang MC et al. Testing the neurovascular hypothesis of Alzheimer's disease: LRP-1 antisense reduces blood-brain barrier clearance and increases brain levels of amyloid-b protein and impairs cognition. J. Alz. Dis. 17(3), 553-570 (2009).
119. Shinohara M, Sato N, Kurinami H et al. Reduction of brain Ab by fluvastatin, an HMG-CoA reductase inhibitor, through increase in degradation of APP-CTFs and Ab clearance. J. Biol. Chem. 285(29) 22091-22102 (2010).
120. Donahue JE, Flaherty SL, Johanson CE et al. RAGE, LRP-1, and amyloid-b protein in Alzheimer's disease. Acta Neuropathol. 112(4), 405-415 (2006).
121. Ito S, Ohtsuki S, Kamiie J, Nezu Y, Terasaki T. Cerebral clearance of human amyloid-b peptide 1-40 across the blood-brain barrier is reduced by self-aggregation and formation of low-density lipoprotein receptor-related protein-1 ligand complexes. J. Neurochem. 103(6), 2482-2490 (2007). (Pubitemid 350173573)
122. Ito S, Ueno T, Ohtsuki S, Terasaki T. Lack of brain-to-blood efflux transport activity of low-density lipoprotein receptor-related protein-1 (LRP-1) for amyloid-b peptide 1-40 in mouse: involvement of an LRP-1-independent pathway. J. Neurochem. 113(5), 1356-1363 (2010).
123. Demeule M, Poirier J, Jodoin J et al. High transcytosis of melanotransferrin (P97) across the blood-brain barrier. J. Neurochem. 83(4), 924-933 (2002). (Pubitemid 35316043)
124. Fillebeen C, Descamps L, Dehouck MP et al. Receptor-mediated transcytosis of lactoferrin through the blood-brain barrier. J. Biol. Chem. 274(11), 7011-7017 (1999).
125. Demeule M, Currie JC, Bertrand Y et al. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. J. Neurochem. 106(4), 1534-1544 (2008).
126. Demeule M, Régina A, Ché C et al. Identification and design of peptides as a new drug delivery system for the brain J. Pharmacol. Exp. Ther. 324(3), 1064-1072 (2008). (Pubitemid 351397849)
127. Ché C, Yang G, Thiot C, et al. New Angiopep-modified doxorubicin (ANG1007) and etoposide (ANG1009) chemotherapeutics with increased brain penetration. J. Med. Chem. 53(7), 2814-2824 (2010).
128. Thomas FC, Taskar K, Rudraraju V et al. Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer. Pharm. Res. 26(11), 2486-2494 (2009).
129. Deane R, Du Yan S, Submamaryan RK et al. RAGE mediates amyloid-b peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med. 9(7), 907-913 (2003). (Pubitemid 36889934)
130. Mackik JB, Stins M, McComb JG et al. Human blood-brain barrier receptors for Alzheimer's amyloid-b1-40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer. J. Clin. Invest. 102(4), 734-743 (1998). (Pubitemid 28399606)
131. Hofmann MA, Drury S, Fu C et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/ calgranulin polypeptides. Cell 97(7), 889-901 (1999). (Pubitemid 29375048)
132. Hori O, Brett J, Slattery T et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J. Biol. Chem. 270(43), 25752-25761 (1995).
133. Yan SD, Chen X, Fu J et al. RAGE and amyloid-b peptide neurotoxicity in Alzheimer's disease. Nature 382(6593), 685-691 (1996). (Pubitemid 26282167)
134. Silverberg GD, Miller MC, Messier AA et al. Amyloid deposition and influx transporter expression at the blood-brain barrier increase in normal aging. J. Neuropathol. Exp. Neurol. 69(1), 98-108 (2010).
135. Miller MC, Tavares R, Johanson CE et al. Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's disease. Brain Res. 1230(273-280 (2008)
136. LaRue B, Hogg E, Sagare A et al. Method for measurement of the blood-brain barrier permeability in the perfused mouse brain: application to amyloid-b peptide in wild type and Alzheimer's Tg2576 mice. J. Neurosci. Methods. 138(1-2), 233-242 (2004). (Pubitemid 39485995)
137. Egleton RD, Mitchell SA, Huber JD et al. Improved bioavailability to the brain of glycosylated Met-enkephalin analogs. Brain Res. 881(1), 37-46 (2000).
138. Polt R, Porreca F, Szab LZ et al. Glycopeptide enkephalin analogues produce analgesia in mice: evidence for penetration of the blood-brain barrier. Proc. Natl Acad. Sci. USA 91(15), 7114-7118 (1994). (Pubitemid 24226813)
139. Bihorel S, Camenisch G, Lemaire C, Scherrmann JM. Influence of breast cancer resistance protein (ABCG2) and P-glycoprotein (ABCB1A) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier. J. Neurochem. 102(6), 1749-1757 (2007). (Pubitemid 47329285)
140. Bihorel S, Camenisch G, Lemaire C, Scherrmann JM. Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar. Pharm. Res. 24(9), 1720-1728 (2007). (Pubitemid 47206611)
141. Cisternino S, Rousselle C, Debray M, Scherrmann JM. In situ transport of vinblastine and selected P-glycoprotein substrates: implications for drug-drug interactions at the mouse blood-brain barrier. Pharm. Res. 21(8), 1382-1389 (2004). (Pubitemid 39149652)
142. Shaik N, Giri N, Pan G, Elmquist WF. P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution. Drug Metab. Dispos. 35(11), 2076-2085 (2007). (Pubitemid 350005198)
143. Lam FC, Liu R, Lu P et al. b-amyloid efflux mediated by p-glycoprotein. J. Neurochem. 76(4), 1121-1128 (2001).
144. Vogelgesang S, Cascorbi I, Schroeder E et al. Deposition of Alzheimer's b-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly nondemented humans. Pharmacogenetics. 12(7), 535-541 (2002). (Pubitemid 35177083)
145. Vogelgesang S, Warzok RW, Cascorbi I et al. The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease. Curr. Alzheimer Res. 1(2), 121-125 (2004).
146. Hartz AM, Miller DS, Bauer B. Restoring blood-brain barrier P-glycoprotein reduces brain Ab in a mouse model of Alzheimer's disease. Mol. Pharmacol. 77(5), 715-723 (2010).
147. Kuhnke D, Jedlitschky G, Grube M et al. MDR1-P-Glycoprotein (ABCB1) mediates transport of Alzheimer's amyloid-b peptides-implications for the mechanisms of Ab clearance at the blood-brain barrier. Brain Pathol. 17(4), 347-353 (2007). (Pubitemid 47537591)
148. Cirrito JR, Deane R, Fagan AM et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-b deposition in an Alzheimer disease mouse model. J. Clin. Invest. 115(11), 3285-3290 (2005). (Pubitemid 41567593)
149. Tai LM, Loughlin AJ, Male DK, Romero IA. P-glycoprotein and breast cancer
150. Ito S, Ohtsuki S, Terasaki T. Functional characterization of the brain-to-blood efflux clearance of human amyloid-b peptide 1-40 across the rat blood-brain barrier. Neurosci. Res. 56(3), 246-242 (2006).
151. Bartels AL, Kortekaas R, Bart J et al. Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration. Neurobiol. Aging 30(11), 1818-1824 (2009).
152. van Berckel B, Lubberink M, Luurtsema G, Boellaard R, Lammertsma A. IC-P3-224: Regional variations in age dependence of P-gp mediated transport across the blood-brain barrier measured using (R)-[11C]verapamil and positron emission tomography. Alzheimers Dement. 4(Suppl. 1), T95 (2008).
153. Pahnke J, Walker LC, Scheffler K, Krohn M. Alzheimer's disease and blood-brain barrier function - why have anti-b-amyloid therapies failed to prevent dementia progression? Neurosci. Biobehav. Rev. 33(7), 1099-1108 (2009).
154. Lagas JS, van Waterschoot RA, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol. Cancer Ther. 9(2), 319-326 (2010).
155. Lagas JS, Van Waterschoot RA, van Tilburg VA et al. Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment. Clin. Cancer Res. 15(7), 2344-2351 (2009).
156. Xiong H, Callaghan D, Jones A et al. ABCG2 is upregulated in Alzheimer's brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-brain barrier for Ab1-40 peptides. J. Neurosci. 29(17), 5463-5475 (2009).
157. Sugiyama D, Kusuhara H, Lee YJ, Sugiyama Y. Involvement of multidrug resistance associated protein 1 (MRP1) in the efflux transport of 17b estradiol-d-17b-glucuronide (E217bG) across the blood-brain barrier. Pharm. Res. 20(9), 1394-1400 (2003). (Pubitemid 37164047)
158. Sultana R, Butterfield DA. Oxidatively modified GST and MRP1 in Alzheimer's disease brain: implications for accumulation of reactive lipid peroxidation products. Neurochem. Res. 29(12), 2215-2220 (2004). (Pubitemid 40036893)
159. Hsiao K, Chapman P, Nilsen S et al. Correlative memory deficits, Ab elevation, and amyloid plaques in transgenic mice. Science 274(5284), 99-102 (1996). (Pubitemid 26332733)
160. Hsiao KK, Borchelt DR, Olson K et al. Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron 15(5), 1203-1218 (1995).
161. Holcomb L, Gordon MN, McGowan E et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 4(1), 97-100 (1998). (Pubitemid 28133087)
162. Takechi R, Galloway S, Pallebage-Gamarallage MM, Mamo JC. Chylomicron amyloid-b in the aetiology of Alzheimer's disease. Atheroscler. Suppl. 9(2), 19-25 (2008).
163. Poduslo JF, Curran GL, Wengenack TM, Malester B, Duff K. Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 8(4), 555-567 (2001). (Pubitemid 32758660)
164. Banks WA, Farr SA, Morley JE. Permeability of the blood-brain barrier to albumin and insulin in the young and aged SAMP8 mouse. J. Gerontol. 55(12), B601-B606 (2000). (Pubitemid 32175751)
165. Ueno M, Akiguchi I, Hosokawa M et al. Age-related changes in barrier function in mouse brain II. Accumulation of serum albumin in the olfactory bulb of SAM mice increased with aging. Arch. Gerentol. Geriatr. 25(3), 321-331 (1997). (Pubitemid 27450397)
166. Ueno M, Akiguchi I, Yagi H et al. Age-related changes in barrier function in mouse brain I. Accelerated age-related increase of brain transfer of serum albumin in accelerated senescence prone SAM-P/8 mice with deficits in learning and memory. Arch. Gerentol. Geriatr. 16(3), 233-248 (1993). (Pubitemid 23224633)
167. Pelegr C, Canudas AM, del Valle J et al. Increased permeability of blood-brain barrier on the hippocampus of a murine model of senescence. Mech. Aging Dev. 128(9), 522-528 (2007). (Pubitemid 47348068)
168. Opazo C, Luza S, Villemagne VL et al. Radioiodinated clioquinol as a biomarker for b-amyloid: Zn complexes in Alzheimer's disease. Aging Cell 5(1), 69-79 (2006). (Pubitemid 43348964)
169. Adlard PA, Cherny RA, Finkelstein DI et al. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Ab. Neuron. 59(1), 43-55 (2008). (Pubitemid 351905863)